Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $13.14

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received an average rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Several equities analysts have issued reports on the stock. UBS Group assumed coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They issued a “neutral” rating for the company. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. TD Cowen cut shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Tuesday, April 21st.

Jasper Therapeutics Stock Performance

Shares of Jasper Therapeutics stock traded down $0.00 on Friday, hitting $0.58. The stock had a trading volume of 1,462,889 shares, compared to its average volume of 467,648. The stock has a 50 day moving average of $0.64 and a 200 day moving average of $1.08. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $3.65. The firm has a market capitalization of $16.23 million, a P/E ratio of -0.18 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. Equities analysts expect that Jasper Therapeutics will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics during the fourth quarter worth about $26,000. Panagora Asset Management Inc. bought a new stake in Jasper Therapeutics in the fourth quarter valued at approximately $35,000. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics during the 1st quarter valued at approximately $46,000. Voleon Capital Management LP acquired a new stake in Jasper Therapeutics during the 3rd quarter valued at approximately $50,000. Finally, Jain Global LLC bought a new position in Jasper Therapeutics during the 4th quarter worth approximately $79,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.